Blue Fin Capital Inc. lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 7.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,280 shares of the medical technology company’s stock after selling 485 shares during the quarter. Blue Fin Capital Inc.’s holdings in Stryker Corporation were worth $871,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Lockheed Martin Investment Management Co. bought a new position in shares of Stryker Corporation during the 2nd quarter worth approximately $1,249,000. JPMorgan Chase & Co. lifted its position in shares of Stryker Corporation by 276.9% during the 1st quarter. JPMorgan Chase & Co. now owns 269,555 shares of the medical technology company’s stock worth $35,487,000 after buying an additional 198,035 shares during the period. BB&T Corp lifted its position in shares of Stryker Corporation by 5.7% during the 2nd quarter. BB&T Corp now owns 56,546 shares of the medical technology company’s stock worth $7,847,000 after buying an additional 3,060 shares during the period. British Columbia Investment Management Corp lifted its position in shares of Stryker Corporation by 10.7% during the 1st quarter. British Columbia Investment Management Corp now owns 133,596 shares of the medical technology company’s stock worth $17,588,000 after buying an additional 12,871 shares during the period. Finally, Hartland & Co. LLC lifted its position in shares of Stryker Corporation by 1.4% during the 1st quarter. Hartland & Co. LLC now owns 1,860 shares of the medical technology company’s stock worth $245,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 74.18% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Blue Fin Capital Inc. Has $871,000 Position in Stryker Corporation (SYK)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://sportsperspectives.com/2017/09/12/blue-fin-capital-inc-has-871000-position-in-stryker-corporation-syk.html.
Several equities analysts recently commented on the company. Zacks Investment Research downgraded Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. BidaskClub downgraded Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Oppenheimer Holdings, Inc. set a $148.00 target price on Stryker Corporation and gave the stock a “hold” rating in a research report on Friday, July 28th. Jefferies Group LLC restated a “hold” rating and set a $132.00 target price on shares of Stryker Corporation in a research report on Friday, June 30th. Finally, Cowen and Company restated a “buy” rating and set a $160.00 target price (up previously from $150.00) on shares of Stryker Corporation in a research report on Sunday, July 30th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $145.73.
Shares of Stryker Corporation (SYK) opened at 143.69 on Tuesday. The stock has a 50 day moving average price of $144.00 and a 200 day moving average price of $138.33. The firm has a market capitalization of $53.75 billion, a PE ratio of 32.07 and a beta of 0.81. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same period in the prior year, the company earned $1.39 EPS. Stryker Corporation’s revenue was up 6.1% compared to the same quarter last year. Equities research analysts anticipate that Stryker Corporation will post $6.46 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s payout ratio is 37.95%.
In other news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the transaction, the insider now directly owns 8,983 shares in the company, valued at approximately $1,313,853.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Floyd sold 19,305 shares of the stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Insiders sold a total of 25,429 shares of company stock valued at $3,686,927 over the last quarter. 7.40% of the stock is owned by corporate insiders.
Stryker Corporation Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.